<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03573869</url>
  </required_header>
  <id_info>
    <org_study_id>39052/21-12-17</org_study_id>
    <nct_id>NCT03573869</nct_id>
  </id_info>
  <brief_title>Atrial FIbrillation Treatment With Cryoballoon in Heart failurE (AFICHE)</brief_title>
  <acronym>AFICHE</acronym>
  <official_title>Effect of Cryoballoon Pulmonary Vein Isolation on Atrial Fibrillation Burden and Clinical Endpoints in Patients With Heart Failure With Impaired Left Ventricular Systolic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>G.Gennimatas General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>G.Gennimatas General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study 404 patients with heart failure and an ejection fraction of 0.40 or less, with
      paroxysmal atrial fibrillation, will be randomly assigned to standard treatment or standard
      treatment plus a session of cryoballoon ablation (left atrial balloon cryoablation for
      pulmonary vein isolation). All patients with either have an ICD or CRT-D/P device implanted
      or an implantable electrocardiographic monitoring device. The primary study endpoint will be
      the time to AF burden exceeding 1% over any 30-day period (calculated as the ratio of time
      spent in AF over total time).16 This AF burden corresponds to 7.2 hours per month.

      A powered secondary endpoint will be the time to the composite of all-cause mortality and
      unplanned hospitalization for heart failure.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to exceed AG burden cut-off of 1%</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The time to AF burden exceeding 1% over any 30-day period (calculated as the ratio of time spent in AF over total time)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality or hospitalization for heart failure</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Time to the composite of all-cause mortality and unplanned hospitalization for heart failure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">404</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Heart Failure, Systolic</condition>
  <arm_group>
    <arm_group_label>Cryoballoon ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A 28-mm cryoballoon (Arctic Front Advanceâ„¢ Cardiac CryoAblation Catheter, Medtronic, Minneapolis, MN) will be employed. The cryoballoon catheter will be introduced into the left atrium, following a single transeptal puncture, through a 12F FlexCath steerable sheath (Medtronic), constantly flushed with heparinized saline. A circular mapping catheter (Achieve, Medtronic) will be advanced through the cryoballoon to the PV orifice and positioned as proximally as possible inside the vessel to record the PV potentials at baseline and monitor the isolation procedure in real time.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard treatment, including at least one rhythm control medication, on top of optimized rate control and HF treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cryoballoon ablation</intervention_name>
    <description>Left atrial ablation using cryoballoon to achieve pulmonary vein isolation</description>
    <arm_group_label>Cryoballoon ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  A minimum of at least two separate AF episodes recorded within the last 12 months,
             either on 12-lead rest ECG or on ambulatory ECG recordings (at least 5 minutes of AF
             on Holter recordings will be required),

          -  LVEF &lt;40% on sinus rhythm,

          -  symptoms consistent with heart failure (New York Heart Association II or higher)
             despite rate control treatment,

          -  age &gt;21 years old.

        Exclusion criteria:

          -  previous left atrial ablation,

          -  left atrial diameter &gt;28 mm/m2 BSA on TTE (parasternal long axis view),

          -  strong clinical suspicion that reduced LVEF is primarily due to tachycardiomyopathy,

          -  pre-existing device (ICD or CRT) without AF detection algorithms and/or (for CRT
             devices) diagnostics of effective biventricular pacing,

          -  known primary electrical heart disease (e.g. Brugada syndrome),

          -  presence of thrombus in a heart chamber,

          -  presence of prosthetic valve at any position,

          -  moderate/severe valvular heart disease,

          -  active infectious disease or malignancy,

          -  moderate or severe hepatic impairment (Child-Pugh class B or C),

          -  severe renal failure (estimated glomerular filtration rate &lt;20 ml/min/1.73 m2),

          -  inability or unwillingness to adhere to standard treatment or to provide consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Athens General Hospital &quot;G. Gennimatas&quot;</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charalampos Kossyvakis, MD, PhD</last_name>
      <phone>00302107768560</phone>
      <email>ckossyvakis@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Georgios Giannopoulos, MD,PhD</last_name>
      <phone>00302107768244</phone>
      <email>ggiann@med.uoa.gr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 8, 2018</study_first_submitted>
  <study_first_submitted_qc>June 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2018</study_first_posted>
  <last_update_submitted>July 6, 2018</last_update_submitted>
  <last_update_submitted_qc>July 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National and Kapodistrian University of Athens</investigator_affiliation>
    <investigator_full_name>Spyridon Deftereos</investigator_full_name>
    <investigator_title>Professor of Cardiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Heart Failure, Systolic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

